We are live on ! Find out more
STAB

Statera Biopharma

Delisted

STAB was delisted on the 11th of January, 2023.

19 hedge funds and large institutions have $681K invested in Statera Biopharma in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

12% more funds holding

Funds holding: 17 → 19 (+2)

0.57% less ownership

Funds ownership: 3.22% → 2.66% (-0.57%)

65% less capital inflows, than outflows

Capital inflows: $89.2K | Capital outflows: $251K

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

STAB Hedge Fund Activity: Q3 2020 in Review

19 of the 4,973 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma (STAB) for Q3 2020, worth a combined $681K — down 36% from $1.07M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new STAB positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was PNC Financial Services Group, opening a new position worth an estimated $34.5K. The largest seller was Renaissance Technologies, cutting an estimated $153K.

  • 19 institutional investors held Statera Biopharma (STAB) as of Q3 2020, up from 17 in Q2 2020.
  • Funds reported $681K of Statera Biopharma stock for Q3 2020, down 36% quarter-over-quarter.
  • 3 funds opened new Statera Biopharma positions in Q3 2020 and 1 closed out, a net change of +2 holders.
  • The largest Statera Biopharma buyer in Q3 2020 was PNC Financial Services Group, an estimated $34.5K added.
  • The largest Statera Biopharma seller in Q3 2020 was Renaissance Technologies, an estimated $153K sold.

Based on aggregated 13F filings for Q3 2020.